Abstract
PURPOSE: Triple-negative breast cancer (TNBC) is a subset of breast cancer which is known to carry a poor prognosis because of lack of targets for hormonal therapy. Research efforts have focused in recent years on discovering biomarkers of management in TNBCs. KI-67 Labelling Index (LI) is a nuclear protein which has proven to play diagnostic and prognostic roles in many cancers.
MATERIALS AND METHODS: We analysed the expression of KI-67 LI by immunohistochemistry in TNBC cases from the University hospital. This expression was cross-checked against clinical-pathological criteria of TNBC patients and against Vimentin expression in TNBC patients with significant KI-67 expression.
RESULTS: KI-67 LI was significantly expressed in the majority of TNBC cases. This expression was significantly correlated with lymph node metastases, tumour invasion. high tumour nuclear grade, clinical stage, adverse survival outcome. and failure to achieve pathological complete response. TNBCs' KI-67 LI expression was also correlated with Vimentin expression. the mesenchymal chief marker of the EMT phenomenon.
CONCLUSION: Collectively, our study presents a strong argument for the use of KI-67 LI as a biomarker of aggressive, metastatic TNBC disease with poor outcome. This study, along with mounting evidence in the scientific literature. presents a case for the use of this nuclear protein in diagnosis. prognosis, and follow-up of patients with this difficult diagnosis.